These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31853685)

  • 21. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.
    Kim SY; An J; Lim YS; Han S; Lee JY; Byun JH; Won HJ; Lee SJ; Lee HC; Lee YS
    JAMA Oncol; 2017 Apr; 3(4):456-463. PubMed ID: 27657493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
    Kim YK; Kim CS; Han YM; Park G
    Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma.
    Yokoo T; Masaki N; Parikh ND; Lane BF; Feng Z; Mendiratta-Lala M; Lee CH; Khatri G; Marsh TL; Shetty K; Dunn CT; Al-Jarrah T; Aslam A; Davenport MS; Gopal P; Rich NE; Lok AS; Singal AG
    Radiology; 2023 Apr; 307(2):e220917. PubMed ID: 36692401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
    An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
    BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinical significance of discordant LI-RADS
    Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
    Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
    Hardie AD; Kizziah MK; Rissing MS
    J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.
    Granata V; Grassi R; Fusco R; Setola SV; Belli A; Piccirillo M; Pradella S; Giordano M; Cappabianca S; Brunese L; Grassi R; Petrillo A; Izzo F
    Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33808466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma.
    Lee JY; Huo EJ; Weinstein S; Santos C; Monto A; Corvera CU; Yee J; Hope TA
    Abdom Radiol (NY); 2018 Jul; 43(7):1627-1633. PubMed ID: 29018942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
    Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
    J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis.
    Zhou Y; Jing X; Zhang X; Ding J; Wang Y; Zhou H; Zhang Q; Chen Y; Yue W
    Ultrasound Med Biol; 2019 Mar; 45(3):693-701. PubMed ID: 30606633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.
    Choi SH; Kim SY; Lee SS; Shim JH; Byun JH; Baek S; Lee MG
    AJR Am J Roentgenol; 2017 Sep; 209(3):584-591. PubMed ID: 28609188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance.
    Kim JS; Lee JK; Baek SY; Yun HI
    Abdom Radiol (NY); 2020 Jan; 45(1):211-219. PubMed ID: 31650374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
    Kurucay M; Kloth C; Kaufmann S; Nikolaou K; Bösmüller H; Horger M; Thaiss WM
    Cancer Imaging; 2017 Jun; 17(1):18. PubMed ID: 28659180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort.
    Park SH; Kim B; Kim SY; Shim YS; Kim JH; Huh J; Kim HJ; Kim KW; Lee SS
    Eur Radiol; 2020 Apr; 30(4):2302-2311. PubMed ID: 31858203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.